Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy.
Pal A, Kundu R. · 2019
Read Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. by Pal A, Kundu R. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6985034.txt.
Introduction
Pal and Kundu review two viral proteins that drive cervical cancer, and how to attack them. Their review appeared in Frontiers in Microbiology. Human papillomavirus causes this cancer, a major killer of women in poorer regions. Late diagnosis and poor outlook drive its toll.
Two viral genes, E6 and E7, run constantly in the cancer cells and are required for the tumour to grow. The authors describe their structure and how they switch on the classic hallmarks of cancer. Therapies that shut E6 and E7 down remove the engine of the disease. Options surveyed include vaccines, gene editing, T-cell therapy, and plant-derived compounds. Each has cut infected cancer cell numbers in studies. Targeting these two proteins, the authors argue, is the sharpest route to treatment.
Catalog record
| CREATOR | Pal A, Kundu R. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy By Asmita Pal, Rita Kundu Published in: Frontiers in Microbiology DOI: 10.3389/fmicb.2019.03116 ABSTRACT Abstract Human papillomavirus (HPV)-induced cervical cancer is a major health issue among women from the poorly/under-developed sectors of the world. It accounts for a high-mortality rate because of its late diagnosis and poor prognosis. Initial establishment and subsequent progression of this form of cancer are completely dependent on two major oncogenes E6 and E7, which are expressed constitutively leading to tumorigenesis. Thus, manipulation of these genes represents the most successful form of cervical cancer therapy. In the present article, information on structural, functional, and clinical dimensions of E6 and E7 activity has been reviewed. The genome organization and protein structure of E6 and E7 have been discussed followed by their mechanism to establish the six major cancer hallmarks in cervical tissues for tumor propagation. The later section of this review article deals with the different modes of therapeutics, which functions by deregulating E6 and E7 activity. Since E6 and E7 are the biomarkers of a cervical cancer cell and are the ones driving the cancer progression, therapeutic approaches targeting E6 and E7 have been proved to be highly efficient in terms of focused removal of abnormally propagating malignant cells. Therapeutics including different forms of vaccines to advanced genome editing techniques, which suppress E6 and E7 activity, have been found to successfully bring down the population of cervical cancer cells infected with HPV. T-cell mediated immunotherapy is another upcoming successful form of treatment to eradicate HPV-infected tumorigenic cells. Additionally, therapeutics using natural compounds from plants or other natural repositories, i.e., phytotherapeutic approaches have also been reviewed here, which prove their anticancer potential through E6 and E7 inhibitory effects. Thus, E6 and E7 repression through any of these methods is a significant approach toward cervical cancer therapy, described in details in this review along with an insight into the signaling pathways and molecular mechanistic of E6 and E7 action. Keywords: human papillomavirus, oncoproteins E6 and E7, cervical cancer, cancer hallmarks, E6 targeted gene therapy, phytotherapy, immunotherapy INTRODUCTION Cervical cancer is continuing to rise as a global concern with around 570,000 cases diagnosed and 311,000 deaths registered in the year 2018 (Bray et al., 2018). This form of cancer although has started to show a decline in the developed countries is still the reason behind the maximum number of cancer deaths among women in around 43 less developed countries (Torre et al., 2017). Around 85% of all the cervical cancer deaths hail from these low income countries, which are 18 times higher than that of the developed countries (LaVigne et al., 2017). This incongruity in the mortality rate between the developed and the developing/underdeveloped countries is due to the lack of proper awareness, screening programs, inaccessibility to proper diagnosis, and efficient treatment procedures along with an increased exposure to the risk factors leading to cervical cancer. Besides the major risk factor-human papillomaviral (HPV) infection, poor hygiene conditions, smoking, oral contraceptives usage, exposure to diethylstilbestrol (DES), and genetic predisposition are particularly common among women from low socio-economic background (American Cancer Society, 2018). Such a clinical scenario definitely calls in for an inexpensive affordable targeted therapeutic approach. Targeted therapeutic approach targets the major factor responsible for cervical cancer, i.e., HPV infection. Although HPV infection cannot singly induce cervical carcinogenesis, it is a primary requisite for most of the cervical cancer cases. This review discusses in detail about the human papillomavirus genome and its major oncogenes E6 and E7, i.e., the builders of six hallmarks of cancer along with a deeper insight into the clinical implications of E6 and E7 disruption through modern day genome editing techniques or phytotherapeutic methods. Thus, this article tries to encompass all the structural features and the biological functions of E6 and E7 oncogenes along with its role as a therapeutic target, helping to gather a comprehensive knowledge about E6 and E7. HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER Human papillomaviruses from the family Papillomaviridae belong to a category of small non-enveloped circular double-stranded DNA viruses, measuring 50–55 nm in diameter (Doorbar et al., 2016). The category includes 300 different genotypes, among which 200 of them are known to be detrimental to humankind (Serrano et al., 2017). From nucleotide sequence comparison of the L1 ORFs of 118 papillomavirus types, papillomaviruses have been classified by the team of de Villiers et al. (2004) into genera, species, types, and subtypes. Including the modifications proposed by Bernard et al. (2010), papillomaviruses from human have been grouped into five genera: alpha (65 types including HPV16, 18, 31, 33, etc.), beta (53 types including HPV5, 9, 49, etc.), gamma (98 types including HPV4, 48, 50, etc.), mu (3 types including HPV1, HPV63, and HPV 204), and nu (HPV41; www.hpvcenter.se as accessed on December 19, 2019). Among them, alpha-papillomaviruses are the most commonly focused group of papillomaviruses since they are known to be responsible for 5% of the cancer occurrences worldwide (Egawa and Doorbar, 2017). They are further subdivided into cutaneous or mucosal types based on their ability to infect the epithelial skin cells or inner tissue lining, respectively, and either low-risk types or high-risk types depending on their association with cervical cancer or precancerous lesions. The high-risk HPVs include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 of mucosal alpha type genus, classified as Group 1 carcinogens; while HPV68 is considered as a probable human carcinogen under group 2A with limited human evidences. On the other hand, HPV26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85, and 97 are considered as possible group 2B carcinogen by International Agency for Research on Cancer (IARC) with limited epidemiological reports (Bouvard et al., 2009). Among the high-risk types, HPV 16 is undoubtedly the most frequently detected genotype in 60.5% of cervical cancer cases, followed by HPV18 (Serrano et al., 2017). Fortunately, HPV-infected cancers have become preventable by the discovery of prophylactic vaccines. There are three such vaccines accessible in the pharmacy, which include Cervarix (GlaxoSmithKline), Gardasil (Merck Inc.), and Gardasil 9 (Merck Inc.), which can target 2, 4, or 9 different HPV types, respectively. At the same time, the mortality chart for cervical cancer, however, does not reflect the clinical success of such vaccination process. The plausible explanation is the unavailability of these vaccines in the underdeveloped countries, which are the major ones building up the mortality percentage. Moreover, the women from the financially challenged section of the population are not exposed to enough screening and diagnostic procedures, owing to many socio-cultural and financial burdens. Since prophylactic vaccines can work only in the early phases, they cannot prevent the development of cervical cancer in such deprived category of population because of their late diagnosis. The scientific community is thus focusing on the development of therapies to combat cervical cancer, which have already established themselves in the women body. This can be facilitated through targeting of the major oncogenes of HPV-driven carcinogenesis, i.e., E6 and E7. E6 and E7 inhibition can help suppress cervical cancer development even in the advanced stages. HUMAN PAPILLOMAVIRUS GENOME AND ITS INTEGRATION INTO THE HOST CELLULAR GENOME The HPV genome structure and the oncogenes